Results 231 to 240 of about 162,494 (358)

Interaction between Sulphinpyrazone and Warfarin [PDF]

, 1981
Adnan Jamil, John Reid, May Messer
openalex   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 778-789, October 2025.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Computer assisted management of warfarin treatment [PDF]

, 1984
Jeffrey L. Anderson
openalex   +1 more source

Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 803-812, October 2025.
The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar, Cathelijne H. van der Wouden, Lisanne E. N. Manson, Heshu Abdullah‐Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Erika Cecchin, Ka‐Chun Cheung, Vera H. M. Deneer, Siv Jonsson, Candace Joefield‐Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cristina L. Dávila‐Fajardo, Vita Dolžan, George P. Patrinos, Munir Pirmohamed, Gere Sunder‐Plassmann, Giuseppe Toffoli, Jesse J. Swen, Ubiquitous Pharmacogenomics Consortium   +37 more
wiley   +1 more source

Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study. [PDF]

Circ Cardiovasc Qual Outcomes
Kim DH, Ko D, Singer DE, Cervone A, Zhang Y, Chen Q, Lin KJ.   +6 more
europepmc   +1 more source

The history of warfarin

Anaesthesia and Intensive Care
Ball, Christine M, Featherstone, Peter J
openaire   +2 more sources

Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy

ESC Heart Failure, Volume 12, Issue 5, Page 3707-3718, October 2025.
Results and clinical implication of repeat endomyocardial biopsy (EMB). Abstract Aims While the diagnostic role of endomyocardial biopsy (EMB) in myocarditis is unquestioned, little is known about its indications and clinical value during long‐term follow‐up.
Anna Baritussio, Andrea Silvio Giordani, Stefania Rizzo, Cristina Vicenzetto, Monica De Gaspari, Elisa Carturan, Giuseppe Toscano, Federico Scognamiglio, Giuseppe Tarantini, Sabino Iliceto, Cristina Basso, Renzo Marcolongo, Alida Linda Patrizia Caforio   +12 more
wiley   +1 more source

Left atrial thrombus after sudden warfarin withdrawal in a 60-year-old woman with atrial fibrillation. [PDF]

CMAJ
Zhou J, Liu H, Wei P.
europepmc   +1 more source

Correction: Effectiveness of Novel Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Patel P, Patel SH, Siddegowda A, Potini BR, Miriyala V, Patel D, Singh N.   +6 more
europepmc   +1 more source

Therapeutic Plasma Exchange After Spontaneous Intracranial Hemorrhage for a Patient With Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia

Journal of Clinical Apheresis, Volume 40, Issue 5, October 2025.
ABSTRACT Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL), macro‐ and micro‐vascular thromboembolic complications. Lupus anticoagulant‐hypoprothrombinemia (LAHPS) may confound the diagnosis and management of bleeding. Catastrophic APS has a category 1 indication for therapeutic plasma exchange (TPE).
Joshua Nicholas, Junaid Wali, Timothy Ellis‐Caleo, Mrigender Singh Virk, Muharrem Yunce   +4 more
wiley   +1 more source